CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Trametinib +1 moredrug
Likely dose
Trametinib 1.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03076164
NCT03076164Phase 2Completed
CompareCT.gov

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Memorial Sloan Kettering Cancer Center·interventional·Posted Mar 10, 2017·Updated Apr 2, 2024

In Brief

A Phase 2 clinical trial evaluating Trametinib and Erlotinib for Lung Adenocarcinoma and 5 related conditions. Completed, enrolled 24 participants across 7 sites.

Detailed Summary

The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated with curative intent.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV, Recurrent Lung Adenocarcinoma, Recurrent Lung Cancer
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 10, 2017
Enrollment StartMar 1, 2017
Primary CompletionDec 18, 2020
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 9.3 years ago

Interventions

Trametinibdrug

Trametinib 1.5mg once daily by mouth

Erlotinibdrug

Erlotinib 75mg once daily by mouth